CY1122523T1 - Πεπτιδια και πεπτιδομιμητικα σε συνδυαστικες χρησεις και αγωγες για υποπληθυσμους πασχοντων απο καρκινο - Google Patents
Πεπτιδια και πεπτιδομιμητικα σε συνδυαστικες χρησεις και αγωγες για υποπληθυσμους πασχοντων απο καρκινοInfo
- Publication number
- CY1122523T1 CY1122523T1 CY20191101352T CY191101352T CY1122523T1 CY 1122523 T1 CY1122523 T1 CY 1122523T1 CY 20191101352 T CY20191101352 T CY 20191101352T CY 191101352 T CY191101352 T CY 191101352T CY 1122523 T1 CY1122523 T1 CY 1122523T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- peptimoimetes
- populations
- treatments
- combination uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις που συμπεριλαμβάνουν πεπτίδια και πεπτιδομιμητικά που μπορούν να χρησιμοποιηθούν για την αγωγή διαταραχών του κυτταρικού πολλαπλασιασμού όπως αυτές οι οποίες συνδέονται με καλοήθη και κακοήθη κύτταρα όγκου. Ενώ η εφεύρεση δεν περιορίζεται σε οποιονδήποτε συγκεκριμένο μηχανισμό, οι ενώσεις της εφεύρεσης εμφανίζονται να λειτουργούν, τουλάχιστον εν μέρει, δια αναστολής του σημείου ελέγχου του κυτταρικού κύκλου G2. Έτσι, οι ενώσεις της εφεύρεσης μπορούν να χρησιμοποιηθούν για την αναστολή της κυτταρικής αύξησης μόνον ή να χρησιμοποιηθούν σε συνδυασμό με μία αγωγή βλάβης νουκλεϊκού οξέος ώστε να ανασταλεί η κυτταρική αύξηση.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838777P | 2013-06-24 | 2013-06-24 | |
| PCT/IB2014/001579 WO2014207556A1 (en) | 2013-06-24 | 2014-06-24 | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122523T1 true CY1122523T1 (el) | 2021-01-27 |
Family
ID=52141164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101352T CY1122523T1 (el) | 2013-06-24 | 2019-12-23 | Πεπτιδια και πεπτιδομιμητικα σε συνδυαστικες χρησεις και αγωγες για υποπληθυσμους πασχοντων απο καρκινο |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9221872B2 (el) |
| EP (1) | EP3013351B1 (el) |
| JP (1) | JP6401255B2 (el) |
| KR (1) | KR102247493B1 (el) |
| CN (1) | CN105324121A (el) |
| AU (1) | AU2014300713B2 (el) |
| BR (1) | BR112015032542A2 (el) |
| CA (1) | CA2916136C (el) |
| CL (1) | CL2015003704A1 (el) |
| CY (1) | CY1122523T1 (el) |
| DK (1) | DK3013351T3 (el) |
| ES (1) | ES2765300T3 (el) |
| HK (1) | HK1219905A1 (el) |
| HR (1) | HRP20192264T1 (el) |
| HU (1) | HUE046873T2 (el) |
| IL (1) | IL243266B (el) |
| LT (1) | LT3013351T (el) |
| MX (1) | MX366341B (el) |
| MY (1) | MY182232A (el) |
| PH (1) | PH12015502855A1 (el) |
| PL (1) | PL3013351T3 (el) |
| PT (1) | PT3013351T (el) |
| RS (1) | RS60180B1 (el) |
| RU (1) | RU2732440C2 (el) |
| SG (1) | SG11201510490VA (el) |
| SI (1) | SI3013351T1 (el) |
| WO (1) | WO2014207556A1 (el) |
| ZA (1) | ZA201600089B (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| PT2968443T (pt) | 2013-03-15 | 2021-12-28 | Protagonist Therapeutics Inc | Análogos de hepcidina e seus usos |
| LT3143037T (lt) | 2014-05-16 | 2021-10-11 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrino tioeterio peptidų antagonistaii |
| CN107206254B (zh) | 2014-07-17 | 2021-08-24 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| SI3464336T1 (sl) | 2016-06-01 | 2022-06-30 | Athira Pharma, Inc. | Spojine |
| WO2019051494A1 (en) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND USES THEREOF |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| CN116082455A (zh) | 2019-07-10 | 2023-05-09 | 领导医疗有限公司 | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 |
| US11845808B2 (en) | 2020-01-15 | 2023-12-19 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| IL302996A (en) | 2020-11-20 | 2023-07-01 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of the interleukin-23 receptor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1483290T1 (sl) * | 2002-01-17 | 2009-02-28 | Takeda Pharmaceutical | Peptidi in peptidomimetiki, ki imajo antiproliferacijsko aktivnost in/ali okrepijo sredstva ali obdelave, ki poškodujejo nukleinsko kislino |
| US7151092B2 (en) * | 2002-10-31 | 2006-12-19 | Metabasis Therapeutics, Inc. | Cytarabine monophosphate prodrugs |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| CN1812805A (zh) * | 2003-06-25 | 2006-08-02 | 坎巴斯有限公司 | 具有免疫调节活性、抗炎活性和抗病毒活性的肽和肽模仿物 |
| RU2010150964A (ru) | 2008-05-14 | 2012-06-20 | Кэнбас Ко., Лтд. (Jp) | Произведенные из свр501 агенты и способы на их основе для ингибирования остановки клеточного цикла g2 и сенсибилизации клеток к повреждающим днк агентам |
-
2014
- 2014-06-24 KR KR1020157036784A patent/KR102247493B1/ko active IP Right Grant
- 2014-06-24 AU AU2014300713A patent/AU2014300713B2/en active Active
- 2014-06-24 WO PCT/IB2014/001579 patent/WO2014207556A1/en active Application Filing
- 2014-06-24 ES ES14818523T patent/ES2765300T3/es active Active
- 2014-06-24 LT LTEP14818523.4T patent/LT3013351T/lt unknown
- 2014-06-24 PT PT148185234T patent/PT3013351T/pt unknown
- 2014-06-24 EP EP14818523.4A patent/EP3013351B1/en active Active
- 2014-06-24 BR BR112015032542A patent/BR112015032542A2/pt not_active Application Discontinuation
- 2014-06-24 RU RU2016101718A patent/RU2732440C2/ru active
- 2014-06-24 CA CA2916136A patent/CA2916136C/en active Active
- 2014-06-24 DK DK14818523.4T patent/DK3013351T3/da active
- 2014-06-24 SI SI201431451T patent/SI3013351T1/sl unknown
- 2014-06-24 CN CN201480035471.4A patent/CN105324121A/zh active Pending
- 2014-06-24 US US14/313,264 patent/US9221872B2/en active Active
- 2014-06-24 PL PL14818523T patent/PL3013351T3/pl unknown
- 2014-06-24 RS RS20191687A patent/RS60180B1/sr unknown
- 2014-06-24 HU HUE14818523A patent/HUE046873T2/hu unknown
- 2014-06-24 SG SG11201510490VA patent/SG11201510490VA/en unknown
- 2014-06-24 MY MYPI2015704731A patent/MY182232A/en unknown
- 2014-06-24 JP JP2016520755A patent/JP6401255B2/ja active Active
- 2014-06-24 MX MX2015017609A patent/MX366341B/es active IP Right Grant
-
2015
- 2015-12-21 IL IL24326615A patent/IL243266B/en active IP Right Grant
- 2015-12-22 PH PH12015502855A patent/PH12015502855A1/en unknown
- 2015-12-22 CL CL2015003704A patent/CL2015003704A1/es unknown
-
2016
- 2016-01-06 ZA ZA2016/00089A patent/ZA201600089B/en unknown
- 2016-07-12 HK HK16108103.9A patent/HK1219905A1/zh unknown
-
2019
- 2019-12-17 HR HRP20192264TT patent/HRP20192264T1/hr unknown
- 2019-12-23 CY CY20191101352T patent/CY1122523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122523T1 (el) | Πεπτιδια και πεπτιδομιμητικα σε συνδυαστικες χρησεις και αγωγες για υποπληθυσμους πασχοντων απο καρκινο | |
| CY1124901T1 (el) | Μεθοδοι αντιμετωπισης του καρκινου του δερματος με χορηγηση αναστολεα pd-1 | |
| CY1121038T1 (el) | Θεραπεια καρκινου μαστου | |
| CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
| CY1123776T1 (el) | Μεθοδοι για την αντιμετωπιση καταστασεων που συνδεονται με την ενεργοποιηση συμπληρωματος εξαρτωμενου απο την μasp-2 | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| CY1119676T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια του καρκινου | |
| PH12015502339B1 (en) | Arylquinazolines | |
| CR20160229A (es) | Inhibidires de bromodominio | |
| CY1122243T1 (el) | Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt | |
| SV2017005373A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
| EA201991622A1 (ru) | Комплексная терапия для лечения рака | |
| EA201891304A1 (ru) | ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| CY1121515T1 (el) | Μεθοδοι και συνθεσεις για την επουλωση πληγων | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| EA201591399A1 (ru) | РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА | |
| MX2023002591A (es) | Interfaces de proteina. | |
| AU2015279834A8 (en) | Use of peptides that block metadherin-SND1 interaction as treatment for cancer | |
| MX2016016507A (es) | Composiciones y metodos para tratar canceres. | |
| PH12021550035A1 (en) | Combination therapy | |
| EA201591709A1 (ru) | 5-бром-индирубины |